![Author ORCID: We display the ORCID iD icon alongside authors names on our website to acknowledge that the ORCiD has been authenticated when entered by the user. To view the users ORCiD record click the icon. [opens in a new tab]](https://www.cambridge.org/engage/assets/public/coe/logo/orcid.png){kind=logo}
Abstract
Cardiolipin (CL), also known as diphosphatidyglycerol, is localized and synthesized exclusively in the mitochondria. This glycerophospholipid was first characterized by Mary Pangborn and McFarlane in 1941. Presently, CL is considered a potential therapeutic target for several neurodegenerative diseases (NDDs). Recent developments in the field of lipidomics indicate that the ratio of monolysocardiolipin-to-native CL is a valuable biomarker for diagnosing NDDs such as Barth Syndrome (BTHS). In this review, the role of lipidomics in understanding the function of CL in NDDs is reviewed.
